HOLON, Israel, October 25, 2017 /PRNewswire/ --
Compugen Ltd. (NASDAQ: CGEN), a leader
in predictive discovery and development of first-in-class
therapeutics for cancer immunotherapy, announced today that the
Company will release its third quarter financial results on
Tuesday, November 7, 2017 before the
U.S. financial markets open. Management will host a live webcast to
review the results and provide a corporate update at 10:00 AM ET.
To access the live conference call by telephone, please dial
1-888-281-1167 from the US, or +972-3-918-0644 internationally. The
call will also be available via live webcast through Compugen's
website, located at the following link. Following the live audio
webcast, a replay will be available on the Company's website.
About Compugen
Compugen is a therapeutic discovery and development company
utilizing its broadly applicable predictive discovery
infrastructure to identify novel drug targets and develop
first-in-class therapeutics in the field of cancer immunotherapy.
The Company's therapeutic pipeline consists of immuno-oncology
programs against novel drug targets it has discovered, including T
cell immune checkpoints and myeloid target programs. Compugen's
business model is to selectively enter into collaborations for its
novel targets and related drug product candidates at various stages
of research and development. The Company is headquartered in
Israel, with R&D facilities in
both Israel and South San Francisco, CA. Compugen's shares are
listed on NASDAQ and the Tel Aviv Stock Exchange under the ticker
symbol CGEN. For additional information, please visit Compugen's
corporate website at http://www.cgen.com.
Company contact:
Elana Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972 (3) 765-8124
SOURCE Compugen Ltd.